Goldman Sachs
HRTX icon

Goldman Sachs’s Heron Therapeutics HRTX Stock Holding History

Goldman Sachs’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-38,500
Closed -$697K – 6107
2017
Q4 		$697K Buy
38,500
+1,100
+3% +$17.9K ﹤0.01% 4570
2017
Q3 		$604K Buy
37,400
+35,700
+2,100% +$560K ﹤0.01% 4968
2017
Q2 		$24K Sell
1,700
-5,500
-76% -$79.7K ﹤0.01% 6522
2017
Q1 		$108K Buy
7,200
+6,000
+500% +$83K ﹤0.01% 6033
2016
Q4 		$16K Sell
1,200
-4,300
-78% -$67.5K ﹤0.01% 6692
2016
Q3 		$95K Buy
5,500
+3,000
+120% +$55.7K ﹤0.01% 6248
2016
Q2 		$45K Sell
2,500
-54,500
-96% -$1.06M ﹤0.01% 6462
2016
Q1 		$1.08M Buy
57,000
+43,100
+310% +$850K ﹤0.01% 4017
2015
Q4 		$371K Sell
13,900
-996,500
-99% -$26.6M ﹤0.01% 5166
2015
Q3 		$24.7M Buy
+1,010,400
New +$33.7M 0.01% 1572

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Goldman Sachs's HRTX Position: Q1 2026 in Review

Goldman Sachs increased its Heron Therapeutics (HRTX) stake by 6.8% in Q1 2026, buying an estimated $77.8K and bringing the position to 1,056,944 shares worth $846K. The position accounts for ﹤0.01% of the portfolio, ranked #5219.

Goldman Sachs first reported a position in HRTX in Q1 2014 and has held it in 46 quarters since. The position peaked at $36.1M in Q4 2019. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Goldman Sachs held 1,056,944 shares of Heron Therapeutics worth $846K as of Q1 2026.
  • Goldman Sachs bought 67,148 Heron Therapeutics shares in Q1 2026, an estimated $77.8K.
  • Heron Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5219 holding.
  • Goldman Sachs first reported a position in Heron Therapeutics in Q1 2014 and has held it in 46 quarters since.
  • Goldman Sachs's Heron Therapeutics position peaked at $36.1M in Q4 2019.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.